RLYB News and Press, Rallybio Corporation From 08/07/25

2025-08-07 09:42:17 ET More on Rallybio Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug Seeking Alpha’s Quant Rating on Rallybio Historical earnings data for Rallybio Financial information for Rallybio Rea...

2025-08-07 09:42:17 ET More on Rallybio Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug Seeking Alpha’s Quant Rating on Rallybio Historical earnings data for Rallybio Financial information for Rallybio Rea...

– Data Readouts from Cohort 1 and Cohort 2 of RLYB116 Confirmatory PK/PD Study on Track for 3Q and 4Q 2025, Respectively – – Sold Interest in REV102 to Recursion Pharmaceuticals for Up to $25 Million, including an Upfront Equity Payment of $7.5 Million – ...

2025-07-08 13:28:49 ET Shares in biotech company Recursion Pharmaceuticals (NASDAQ: RXRX) surged by more than 12% by 11 a.m. ET today. The move is due to a de-risking event in its drug discovery pipeline. The de-risking event relates to the acquisition of the 50% interest in an ...

2025-07-08 08:39:40 ET More on Rallybio, Recursion Pharmaceuticals Recursion: Lack Of Near-Term Catalysts Leaves The Stock Vulnerable Recursion Pharmaceuticals: Recent Readouts Disappointing, Future Readouts Risky Recursion Pharmaceuticals: High-Risk Play Getting Ris...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific ad...

– Potential to Address a Broad Range of Complement-Mediated Diseases with Initial Focus on Immune Platelet Transfusion Refractoriness and Refractory Antiphospholipid Syndrome – – Data Readouts Expected from Cohort 1 in 3Q 2025 and Cohort 2 in 4Q 2025 – ...

2025-05-08 10:36:25 ET More on Rallybio Seeking Alpha’s Quant Rating on Rallybio Historical earnings data for Rallybio Financial information for Rallybio Read the full article on Seeking Alpha For further details see: Rallybio GAAP EPS of -...

– On Track to Initiate Dosing in RLYB116 Confirmatory PK/PD Study in 2Q 2025, with Multiple Data Readouts Anticipated in 2H 2025 – – $54.5 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2025 Provides Runway into 1H 2027 – ...

Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $-0.05 for Q1 2025 CaliberCos Inc. (CWD) is expected to report $-0.4 for Q1 2025 BlackRock TCP Capital Corp. (TCPC) is expected to report $0.34 for Q1 2025 INmune Bio Inc. (INMB) is expected to report $-0.43 for Q1 2025 No...